{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:46:31Z","timestamp":1790729191513,"version":"4.1.0"},"reference-count":168,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.arbres.2025.10.021","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:57:45Z","timestamp":1768463865000},"page":"387-399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Recommendations on the Diagnosis and Treatment of Tuberculosis Infection: SEPAR\/SEIMC\/Spanish Ministry of Health Consensus Statement"],"prefix":"10.1016","volume":"62","author":[{"given":"Jos\u00e9 Antonio","family":"Caminero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00eds","family":"Anibarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Alcaide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"P\u00e9rez-Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan-Pau","family":"Millet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remedio","family":"Guna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Luiza","family":"de Souza-Galv\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"L\u00f3pez-Roa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"S\u00e1nchez-Montalv\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Gull\u00f3n-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Gonz\u00e1lez-Gal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.arbres.2025.10.021_bib0005","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00021-18","article-title":"Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection","volume":"31","author":"Drain","year":"2018","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl. 4","key":"10.1016\/j.arbres.2025.10.021_bib0010","doi-asserted-by":"crossref","first-page":"S1179","DOI":"10.1093\/infdis\/jir451","article-title":"Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response","volume":"204","author":"Achkar","year":"2011","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.arbres.2025.10.021_bib0015","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S2213-2600(24)00028-6","article-title":"Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise","volume":"12","author":"Coussens","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.arbres.2025.10.021_bib0020","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2214-109X(24)00083-4","article-title":"A global tuberculosis dictionary: unified terms and definitions for the field of tuberculosis","volume":"12","author":"Garcia-Basteiro","year":"2024","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.arbres.2025.10.021_bib0025","unstructured":"Report of the WHO consultation on asymptomatic tuberculosis, Geneva, Switzerland, 14\u201315 October 2024. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"10.1016\/j.arbres.2025.10.021_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(25)00092-X","article-title":"Unveiling a hidden phenotype of early tuberculosis","author":"Ehrlich","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2025.10.021_bib0035","series-title":"Module 1: prevention \u2013 tuberculosis preventive treatment second edition","year":"2024"},{"key":"10.1016\/j.arbres.2025.10.021_bib0040","series-title":"Global Tuberculosis Report 2024","year":"2024"},{"issue":"10","key":"10.1016\/j.arbres.2025.10.021_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling","volume":"13","author":"Houben","year":"2016","journal-title":"PLoS Med"},{"issue":"22","key":"10.1016\/j.arbres.2025.10.021_bib0050","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1001\/jama.293.22.2767","article-title":"Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally","volume":"293","author":"Dye","year":"2005","journal-title":"JAMA"},{"issue":"27","key":"10.1016\/j.arbres.2025.10.021_bib0055","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000043202","article-title":"Retrospective evaluation of active tuberculosis cases in terms of chemoprophylaxis indication: a cross-sectional study","volume":"104","author":"Ongoz","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.arbres.2025.10.021_bib0060","series-title":"Instituto de Salud Carlos III. Informe epidemiol\u00f3gico sobre la situaci\u00f3n de la tuberculosis en Espa\u00f1a","year":"2023"},{"issue":"1","key":"10.1016\/j.arbres.2025.10.021_bib0065","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s12890-022-02149-x","article-title":"A systematic review of cost-utility analyses of screening methods in latent tuberculosis infection in high-risk populations","volume":"22","author":"Mahon","year":"2022","journal-title":"BMC Pulm Med"},{"issue":"12","key":"10.1016\/j.arbres.2025.10.021_bib0070","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/s41591-020-1076-0","article-title":"Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings","volume":"26","author":"Gupta","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.arbres.2025.10.021_bib0075","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.arbres.2010.02.010","article-title":"Consensus document on the diagnosis, treatment and prevention of tuberculosis","volume":"46","author":"Gonz\u00e1lez-Mart\u00edn","year":"2010","journal-title":"Arch Bronconeumol"},{"issue":"5","key":"10.1016\/j.arbres.2025.10.021_bib0080","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.eimc.2015.11.021","article-title":"Executive summary of the guidelines for the use of interferon-\u03b3 release assays in the diagnosis of tuberculosis infection","volume":"34","author":"Santin","year":"2016","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"22","key":"10.1016\/j.arbres.2025.10.021_bib0085","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMra1405427","article-title":"Latent Mycobacterium tuberculosis infection","volume":"372","author":"Getahun","year":"2015","journal-title":"Engl N J Med"},{"issue":"5","key":"10.1016\/j.arbres.2025.10.021_bib0090","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1172\/JCI97508","article-title":"Mycobacterial growth inhibition is associated with trained innate immunity","volume":"128","author":"Joosten","year":"2018","journal-title":"J Clin Invest"},{"issue":"25","key":"10.1016\/j.arbres.2025.10.021_bib0095","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1016\/j.cell.2022.10.025","article-title":"Immune cell interactions in tuberculosis","volume":"185","author":"Flynn","year":"2022","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.arbres.2025.10.021_bib0100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tube.2013.07.004","article-title":"A new unifying theory of the pathogenesis of tuberculosis","volume":"94","author":"Orme","year":"2014","journal-title":"Tuberculosis (Edinb)"},{"issue":"5","key":"10.1016\/j.arbres.2025.10.021_bib0105","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MGM2-0005-2013","article-title":"Evasion of innate and adaptive immunity by Mycobacterium tuberculosis","volume":"2","author":"Goldberg","year":"2014","journal-title":"Microbiol Spectr"},{"issue":"10","key":"10.1016\/j.arbres.2025.10.021_bib0110","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1128\/IAI.00592-09","article-title":"Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model","volume":"77","author":"Lin","year":"2009","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.arbres.2025.10.021_bib0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2008.11.014","article-title":"The role of the granuloma in expansion and dissemination of early tuberculous infection","volume":"136","author":"Davis","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.arbres.2025.10.021_bib0120","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fimmu.2020.00103","article-title":"Cell-mediated immune responses to in vivo-expressed and stage-specific Mycobacterium tuberculosis antigens in latent and active tuberculosis across different age groups","volume":"11","author":"Coppola","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.arbres.2025.10.021_bib0125","doi-asserted-by":"crossref","first-page":"k2738","DOI":"10.1136\/bmj.k2738","article-title":"Revisiting the timetable of tuberculosis","volume":"362","author":"Behr","year":"2018","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.arbres.2025.10.021_bib0130","doi-asserted-by":"crossref","first-page":"562","DOI":"10.37201\/req\/115.2023","article-title":"Tuberculosis in Spain: an opinion paper","volume":"36","author":"Moreno Guill\u00e9n","year":"2023","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.arbres.2025.10.021_bib0135","article-title":"Plan para la prevenci\u00f3n y control de la tuberculosis en Espa\u00f1a. Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacionalde Salud. Ministerio de Sanidad","year":"2019","journal-title":"Consumo y Bienestar Social"},{"issue":"3","key":"10.1016\/j.arbres.2025.10.021_bib0140","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00655-2019","article-title":"The global prevalence of latent tuberculosis: a systematic review and meta-analysis","volume":"54","author":"Cohen","year":"2019","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.arbres.2025.10.021_bib0145","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.282.7.677","article-title":"Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project","volume":"282","author":"Dye","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.arbres.2025.10.021_bib0150","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijid.2022.05.029","article-title":"Prevalence trends of latent tuberculosis infection at the global, regional, and country levels from 1990\u20132019","volume":"122","author":"Ding","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.arbres.2025.10.021_bib0155","first-page":"117","article-title":"The relationship between the risk of tuberculous infection and the risk of developing infectious tuberculosis","volume":"60","author":"Styblo","year":"1985","journal-title":"Bull Int Union Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.arbres.2025.10.021_bib0160","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2471\/BLT.06.037804","article-title":"Prevalence of tuberculous infection and incidence of tuberculosis: a re-assessment of the Styblo rule","volume":"86","author":"van Leth","year":"2008","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.arbres.2025.10.021_bib0165","article-title":"Informe del a\u00f1o 2023 SG Vigilancia en Salud P\u00fablica. Direcci\u00f3n General de Salud P\u00fablica","year":"2023","journal-title":"Consejer\u00eda de Sanidad-Comunidad de Madrid"},{"key":"10.1016\/j.arbres.2025.10.021_bib0170","unstructured":"Informe da tuberculose en Galicia. Caracter\u00edsticas dos casos de tuberculose de Galicia no ano 2023. Evoluci\u00f3n do per\u00edodo 1996\u20132023. Available from: http:\/\/www.sergas.es\/Saude-publica\/Vixilancia-epidemioloxica-da-TB-en-Galicia [accessed 11.1.25]."},{"key":"10.1016\/j.arbres.2025.10.021_bib0175","series-title":"La Tuberculosi a Barcelona. Informe 2022","author":"Millet","year":"2024"},{"issue":"9","key":"10.1016\/j.arbres.2025.10.021_bib0180","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.eimc.2017.10.010","article-title":"Sequential strategy for the LTBI screening of newly-arrived immigrants in vulnerable social situations","volume":"36","author":"Serre-Delcor","year":"2018","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"issue":"1","key":"10.1016\/j.arbres.2025.10.021_bib0185","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4269\/ajtmh.17-0604","article-title":"Newly arrived African migrants to Spain: epidemiology and burden of disease","volume":"98","author":"Salas-Coronas","year":"2018","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.arbres.2025.10.021_bib0190","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens14020175","article-title":"Exposure time to a tuberculosis index case as a marker of infection in immigrant populations","volume":"14","author":"Godoy","year":"2025","journal-title":"Pathogens"},{"issue":"3","key":"10.1016\/j.arbres.2025.10.021_bib0195","first-page":"79","article-title":"Multi-centre study of the prevalence of latent tuberculosis infection amongst inmates in Spanish prisons","volume":"12","author":"Garc\u00eda-Guerrero","year":"2010","journal-title":"Rev Esp Sanid Penit"},{"issue":"1","key":"10.1016\/j.arbres.2025.10.021_bib0200","first-page":"4","article-title":"Prevalence and associated risk factors of latent tuberculosis infection in a Spanish prison","volume":"20","author":"L\u00f3pez de Goicoechea-Saiz","year":"2018","journal-title":"Rev Esp Sanid Penit"},{"issue":"3","key":"10.1016\/j.arbres.2025.10.021_bib0205","doi-asserted-by":"crossref","first-page":"104","DOI":"10.18176\/resp.00076","article-title":"Interferon-gamma release assay for the diagnosis of latent tuberculosis infection in the prison population with a positive tuberculin test: a descriptive study in a prison (Burgos Spain)","volume":"25","author":"Baca","year":"2023","journal-title":"Rev Esp Sanid Penit"},{"issue":"2","key":"10.1016\/j.arbres.2025.10.021_bib0210","doi-asserted-by":"crossref","first-page":"97","DOI":"10.12961\/aprl.2014.17.2.05","article-title":"Latent tuberculosis infection in healthcare personnel at a primary level general hospital in Catalonia Spain","volume":"17","author":"Sol Vidiella","year":"2014","journal-title":"Arch Prev Riesgos Labor"},{"issue":"4","key":"10.1016\/j.arbres.2025.10.021_bib0215","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.rmed.2012.12.008","article-title":"Incidence of tuberculosis infection among healthcare workers: risk factors and 20-year evolution","volume":"107","author":"Casas","year":"2013","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.arbres.2025.10.021_bib0220","doi-asserted-by":"crossref","first-page":"278","DOI":"10.5588\/ijtld.19.0365","article-title":"Vitamin D status and latent tuberculosis infection: conversion in nursing homes, Spain","volume":"24","author":"Arnedo-Pena","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"10.1016\/j.arbres.2025.10.021_bib0225","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taae037","article-title":"Tuberculosis among children visiting friends & relatives","volume":"31","author":"Perez-Porcuna","year":"2024","journal-title":"J Travel Med"},{"issue":"5","key":"10.1016\/j.arbres.2025.10.021_bib0230","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.reuma.2016.05.006","article-title":"How many patients with rheumatic diseases and TNF inhibitors treatment have latent tuberculosis?","volume":"13","author":"Busquets-P\u00e9rez","year":"2017","journal-title":"Reumatol Clin"},{"issue":"1","key":"10.1016\/j.arbres.2025.10.021_bib0235","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00431-022-04640-3","article-title":"Dual latent tuberculosis screening with tuberculin skin tests and QuantiFERON-TB assays before TNF-\u03b1 inhibitor initiation in children in Spain","volume":"182","author":"Calzada-Hern\u00e1ndez","year":"2023","journal-title":"Eur J Pediatr"},{"issue":"10","key":"10.1016\/j.arbres.2025.10.021_bib0240","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.arbr.2018.04.008","article-title":"Screening for latent tuberculosis infection in patients who are candidate for biological therapies in Spain? A multidisciplinary survey","volume":"54","author":"Quir\u00f3s","year":"2018","journal-title":"Arch Bronconeumol (Engl Ed)"},{"issue":"1","key":"10.1016\/j.arbres.2025.10.021_bib0245","first-page":"58","article-title":"From immunology to artificial intelligence: revolutionizing latent tuberculosis infection diagnosis with machine learning","volume":"10","author":"Li","year":"2023","journal-title":"Mil Med Res"},{"issue":"8","key":"10.1016\/j.arbres.2025.10.021_bib0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183258","article-title":"QuantiFERON\u00ae-TB Gold In-Tube for contact screening in BCG-vaccinated adults: a longitudinal cohort study","volume":"12","author":"Mu\u00f1oz","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.arbres.2025.10.021_bib0255","series-title":"QuantiFERON\u00ae-TB Gold Plus (QFT\u00ae-Plus) ELISA package insert","year":"2019"},{"issue":"11","key":"10.1016\/j.arbres.2025.10.021_bib0260","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1093\/cid\/ciad030","article-title":"Assessing the diagnostic performance of new commercial interferon-\u03b3 release assays for Mycobacterium tuberculosis infection: a systematic review and meta-analysis","volume":"76","author":"Ortiz-Brizuela","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.arbres.2025.10.021_bib0265","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00603-21","article-title":"Evaluation of the fully automated chemiluminescence analyzer liaison XL for the performance of the quantiFERON-TB gold plus assay in an area with a low incidence of tuberculosis","volume":"59","author":"Fern\u00e1ndez-Huerta","year":"2021","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.arbres.2025.10.021_bib0270","series-title":"T-SPOT.TB package insert","year":"2017"},{"issue":"5","key":"10.1016\/j.arbres.2025.10.021_bib0275","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.resinv.2023.04.010","article-title":"Current status and future landscape of diagnosing tuberculosis infection","volume":"61","author":"Kobashi","year":"2023","journal-title":"Respir Investig"},{"key":"10.1016\/j.arbres.2025.10.021_bib0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109132","article-title":"Positive rates of interferon-\u03b3 release assay and tuberculin skin test in detection of latent tuberculosis infection: a systematic review and meta-analysis of 200,000 head-to-head comparative tests","volume":"245","author":"Zhou","year":"2022","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1016\/j.arbres.2025.10.021_bib0285","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/thoraxjnl-2015-207811","article-title":"Effect of immunosuppressive therapy on interferon \u03b3 release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"71","author":"Wong","year":"2016","journal-title":"Thorax"},{"issue":"8","key":"10.1016\/j.arbres.2025.10.021_bib0290","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00296-023-05320-7","article-title":"Do the drug doses of conventional synthetic DMARDs used for the treatment of biologic\/targeted-synthetic DMARDs naive rheumatoid arthritis patients affect QuantiFERON-TB Gold Plus test results?","volume":"43","author":"Ozsoy","year":"2023","journal-title":"Rheumatol Int"},{"issue":"23","key":"10.1016\/j.arbres.2025.10.021_bib0295","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMcp021045","article-title":"Clinical practice Latent tuberculosis infection","volume":"347","author":"Jasmer","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2025.10.021_bib0300","series-title":"Handbook on tuberculosis laboratory diagnostic methods in the European Union \u2013 Updated 2022","year":"2023"},{"issue":"4","key":"10.1016\/j.arbres.2025.10.021_bib0305","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S2213-2600(16)30436-2","article-title":"Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon \u03b3 release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial","volume":"5","author":"Ruhwald","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.arbres.2025.10.021_bib0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2024.10.016","article-title":"Agreement between Mycobacterium tuberculosis antigen-based skin test and interferon-gamma release assay in elderly individuals aged \u226565 years in China","volume":"31","author":"He","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"10.1016\/j.arbres.2025.10.021_bib0315","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens13121050","article-title":"Diagnostic accuracy of Mycobacterium tuberculosis antigen-based skin tests (TBSTs) for tuberculosis infection compared with TST and IGRA: a network meta-analysis","volume":"13","author":"Peng","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.arbres.2025.10.021_bib0320","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiaf332","article-title":"Safety and diagnostic performance of recombinant fusion protein ESAT6-CPF10 skin test in a large population: a phase IV clinical trial","author":"Chen","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.arbres.2025.10.021_bib0325","series-title":"Module 3: diagnosis Tests for tuberculosis infection","year":"2022"},{"key":"10.1016\/j.arbres.2025.10.021_bib0330","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3389\/fimmu.2020.01470","article-title":"An RNA-seq based machine learning approach identifies latent tuberculosis patients with an active tuberculosis profile","volume":"11","author":"Est\u00e9vez","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.arbres.2025.10.021_bib0335","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiae642","article-title":"Predictive markers of incident tuberculosis in close contacts in Brazil and India","author":"Nogueira","year":"2025","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.arbres.2025.10.021_bib0340","doi-asserted-by":"crossref","first-page":"e1355","DOI":"10.1093\/infdis\/jiae237","article-title":"Transcriptomic signatures of progression to tuberculosis disease among close contacts in Brazil","volume":"230","author":"Mendelsohn","year":"2024","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.arbres.2025.10.021_bib0345","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.4769","article-title":"Comparison of tuberculin skin testing and interferon-\u03b3 release assays in predicting tuberculosis disease","volume":"7","author":"Ayers","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.arbres.2025.10.021_bib0350","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12879-023-08008-2","article-title":"Comparing the diagnostic performance of QuantiFERON-TB Gold Plus with QFT-GIT T-SPOT.TB and TST: a systematic review and meta-analysis","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.arbres.2025.10.021_bib0355","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.arbres.2020.04.011","article-title":"Diagnosis of tuberculous infection in immunosuppressed patients and\/or candidates for biologics using a combination of 2 IGRA tests: T-SPOT.TB\/QuantiFERON TB gold in-tube vs T-SPOT.TB\/QuantiFERON TB gold plus","volume":"58","author":"Fern\u00e1ndez-Bl\u00e1zquez","year":"2022","journal-title":"Arch Bronconeumol"},{"issue":"3","key":"10.1016\/j.arbres.2025.10.021_bib0360","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/cid\/cix745","article-title":"QuantiFERON-TB gold in-tube as a confirmatory test for tuberculin skin test in tuberculosis contact tracing: a noninferiority clinical trial","volume":"66","author":"Mu\u00f1oz","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arbres.2025.10.021_bib0365","doi-asserted-by":"crossref","DOI":"10.1136\/thorax-2024-222400","article-title":"Combining tuberculin skin test with follow-on interferon gamma release assay markedly improves screening of household contacts","author":"Chan","year":"2025","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.arbres.2025.10.021_bib0370","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S1473-3099(20)30276-0","article-title":"Interferon-\u03b3 release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis","volume":"20","author":"Zhou","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.arbres.2025.10.021_bib0375","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3390\/jpm12030507","article-title":"Impact of immunosuppressive therapy on the performance of latent tuberculosis screening tests in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"12","author":"Park","year":"2022","journal-title":"J Pers Med"},{"issue":"5","key":"10.1016\/j.arbres.2025.10.021_bib0380","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1183\/09031936.00125714","article-title":"An evaluation of the use of a negative interferon-\u03b3 release assay for tuberculosis screening before TNF antagonist therapy","volume":"44","author":"Woodfield","year":"2014","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.arbres.2025.10.021_bib0385","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1183\/09031936.00030610","article-title":"Interferon-gamma release assays in tuberculosis contacts: is there a window period?","volume":"37","author":"Anibarro","year":"2011","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.arbres.2025.10.021_bib0390","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00915-2024","article-title":"Time interval for QuantiFERON-TB Gold Plus conversion after last exposure with tuberculosis","volume":"11","author":"Kyaw","year":"2025","journal-title":"ERJ Open Res"},{"issue":"3","key":"10.1016\/j.arbres.2025.10.021_bib0395","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/ciu796","article-title":"Prevention of anti-tumor necrosis factor-associated tuberculosis: a 10-year longitudinal cohort study","volume":"60","author":"Mu\u00f1oz","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.arbres.2025.10.021_bib0400","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1093\/cid\/ciaa519","article-title":"Predictors of discordant tuberculin skin test and QuantiFERON-TB gold in-tube results in Eastern China: a population-based, cohort study","volume":"72","author":"Lu","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arbres.2025.10.021_bib0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101815","article-title":"Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis","volume":"56","author":"Hamada","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1016\/j.arbres.2025.10.021_bib0410","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.anpedi.2023.03.011","article-title":"Update on the diagnosis and treatment of tuberculosis","volume":"98","author":"Baquero-Artigao","year":"2023","journal-title":"An Pediatr (Engl Ed)"},{"key":"10.1016\/j.arbres.2025.10.021_bib0415","article-title":"Prevention of tuberculosis in patients treated with biological therapies: twenty years\u2019 experience in a specialised tuberculosis clinic in a low-prevalence country","author":"P\u00e9rez-Recio","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arbres.2025.10.021_bib0420","series-title":"Guidelines on the management of latent tuberculosis infection (WHO\/HTM\/TB\/2015.01)","year":"2015"},{"issue":"2","key":"10.1016\/j.arbres.2025.10.021_bib0425","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.chest.2015.11.017","article-title":"Risk of active tuberculosis in the five years following infection. 15%?","volume":"149","author":"Trauer","year":"2016","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.arbres.2025.10.021_bib0430","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1164\/rccm.201406-1159OC","article-title":"Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam","volume":"190","author":"Sloot","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"6\u20137","key":"10.1016\/j.arbres.2025.10.021_bib0435","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/00365548.2011.558912","article-title":"Tuberculin skin test and interferon-\u03b3 release assay show better correlation after the tuberculin \u2018window period\u2019 in tuberculosis contacts","volume":"43","author":"Anibarro","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.arbres.2025.10.021_bib0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.02.025","article-title":"Interferon-gamma release assay conversion after Mycobacterium tuberculosis exposure specifically associates with greater risk of progression to tuberculosis: a prospective cohort study in Leicester, UK","volume":"141","author":"Kim","year":"2024","journal-title":"Int J Infect Dis"},{"issue":"2","key":"10.1016\/j.arbres.2025.10.021_bib0445","article-title":"Updates on the risk factors for latent tuberculosis reactivation and their managements","volume":"5","author":"Ai","year":"2016","journal-title":"Emerg Microbes Infect"},{"issue":"6","key":"10.1016\/j.arbres.2025.10.021_bib0450","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","article-title":"Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries","volume":"46","author":"Getahun","year":"2015","journal-title":"Eur Respir J"},{"issue":"17","key":"10.1016\/j.arbres.2025.10.021_bib0455","first-page":"1662","article-title":"A trial of mass isoniazid preventive therapy for tuberculosis control","volume":"370","author":"Churchyard","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.arbres.2025.10.021_bib0460","first-page":"555","article-title":"International union against tuberculosis committee on prophylaxis","volume":"60","year":"1982","journal-title":"Bull World Health Organ"},{"issue":"11","key":"10.1016\/j.arbres.2025.10.021_bib0465","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.arbres.2013.07.009","article-title":"Inactive fibrotic lesions versus pulmonary tuberculosis with negative bacteriology","volume":"50","author":"Solsona Peiro","year":"2014","journal-title":"Arch Bronconeumol"},{"issue":"1","key":"10.1016\/j.arbres.2025.10.021_bib0470","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7883\/yoken.JJID.2023.277","article-title":"Pulmonary tuberculosis incidence among interferon-gamma release assay-positive individuals with latent tuberculosis infection and fibrotic lesions in a vulnerable urban population in Osaka City, Japan, 2015\u20132021","volume":"77","author":"Komukai","year":"2024","journal-title":"Jpn J Infect Dis"},{"issue":"4","key":"10.1016\/j.arbres.2025.10.021_bib0475","doi-asserted-by":"crossref","first-page":"01231","DOI":"10.1183\/23120541.01231-2024","article-title":"Association of inactive pulmonary tuberculosis lesions with the risk of active disease development in the elderly: a population-based retrospective study","volume":"11","author":"Shen","year":"2025","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.arbres.2025.10.021_bib0480","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1494283","article-title":"Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents","volume":"16","author":"Picchianti-Diamanti","year":"2025","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.arbres.2025.10.021_bib0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103758","article-title":"Assessment and management for latent tuberculosis before advanced therapies for immune-mediated inflammatory diseases: a comprehensive review","volume":"24","author":"Jha","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.arbres.2025.10.021_bib0490","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/cid\/ciab935","article-title":"Joint associations of multiple lifestyle factors with risk of active tuberculosis in the population: the Singapore Chinese Health Study","volume":"75","author":"Li","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arbres.2025.10.021_bib0495","article-title":"Effectiveness and cost-effectiveness of expanded targeted testing and treatment of latent tuberculosis infection among the medicare population in 2022","author":"Li","year":"2025","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.arbres.2025.10.021_bib0500","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.arbres.2024.08.001","article-title":"Executive Summary: Clinical Practice Guidelines on the Management of Resistant Tuberculosis of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)","volume":"60","author":"Sanchez-Montalva","year":"2024","journal-title":"Arch Bronconeumol"},{"issue":"4","key":"10.1016\/j.arbres.2025.10.021_bib0505","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1183\/09031936.00201609","article-title":"Tuberculosis contact investigation in low prevalence countries: a European consensus","volume":"36","author":"Erkens","year":"2010","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.arbres.2025.10.021_bib0510","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2214-109X(24)00481-9","article-title":"Tuberculosis and people who use drugs: why focus on this overlooked population is important and why adapted interventions are necessary","volume":"13","author":"D\u2019Ottavi","year":"2025","journal-title":"Lancet Glob Health"},{"issue":"12","key":"10.1016\/j.arbres.2025.10.021_bib0515","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1164\/rccm.200409-1200OC","article-title":"Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis","volume":"171","author":"Verver","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.arbres.2025.10.021_bib0520","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1473-3099(22)00494-7","article-title":"National survey in South Africa reveals high tuberculosis prevalence among previously treated people","volume":"22","author":"Marx","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.arbres.2025.10.021_bib0525","series-title":"Module 2: screening \u2013 systematic screening for tuberculosis disease","year":"2021"},{"key":"10.1016\/j.arbres.2025.10.021_bib0530","article-title":"Diagnostic accuracy of TB screening tests in a prospective multinational cohort: Chest-X-ray with computer-aided detection Xpert TB host response, and C-reactive protein","author":"Crowder","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arbres.2025.10.021_bib0535","first-page":"490","article-title":"Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts","volume":"85","author":"Ferebee","year":"1962","journal-title":"Am Rev Respir Dis"},{"issue":"6","key":"10.1016\/j.arbres.2025.10.021_bib0540","first-page":"935","article-title":"A controlled trial of community-wide isoniazid prophylaxis in Alaska","volume":"95","author":"Comstock","year":"1967","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.arbres.2025.10.021_bib0545","first-page":"28","article-title":"Controlled chemoprophylaxis trials in tuberculosis. A general review","volume":"26","author":"Ferebee","year":"1970","journal-title":"Bibl Tuberc"},{"key":"10.1016\/j.arbres.2025.10.021_bib0550","first-page":"151","article-title":"Risk of tuberculosis among persons with \u201cnot active \u2013 not treated\u201d lesions","volume":"47","author":"Edwards","year":"1972","journal-title":"Bull Int Union Tuberc"},{"issue":"1","key":"10.1016\/j.arbres.2025.10.021_bib0555","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1378\/chest.73.1.44","article-title":"Prophylaxis with isoniazid in inactive tuberculosis. A Veterans administration cooperative study XII","volume":"73","author":"Falk","year":"1978","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.arbres.2025.10.021_bib0560","first-page":"827","article-title":"Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies","volume":"119","author":"Comstock","year":"1979","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"10.1016\/j.arbres.2025.10.021_bib0565","first-page":"36","article-title":"Hong Kong Chest Service\/Tuberculosis Research Centre Madras\/British Medical Research Council","volume":"145","year":"1992","journal-title":"Am Rev Respir Dis"},{"issue":"8866","key":"10.1016\/j.arbres.2025.10.021_bib0570","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0140-6736(93)91817-6","article-title":"Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection","volume":"342","author":"Pape","year":"1993","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.arbres.2025.10.021_bib0575","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM199709183371201","article-title":"A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration","volume":"337","author":"Whalen","year":"1997","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.arbres.2025.10.021_bib0580","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1056\/NEJM199707313370505","article-title":"A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis Terry Beirn Community Programs for Clinical Research on AIDS","volume":"337","author":"Gordin","year":"1997","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.arbres.2025.10.021_bib0585","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00002030-199707000-00006","article-title":"Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial","volume":"11","author":"Hawken","year":"1997","journal-title":"Aids"},{"issue":"5","key":"10.1016\/j.arbres.2025.10.021_bib0590","first-page":"780","article-title":"How much isoniazid is needed for prophylaxis?","volume":"101","author":"Comstock","year":"1970","journal-title":"Am Rev Respir Dis"},{"issue":"10","key":"10.1016\/j.arbres.2025.10.021_bib0595","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"10.1016\/j.arbres.2025.10.021_bib0600","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M17-0609","article-title":"Treatment of latent tuberculosis infection: an updated network meta-analysis","volume":"167","author":"Zenner","year":"2017","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.arbres.2025.10.021_bib0605","first-page":"371","volume":"110","year":"1974","journal-title":"Am Rev Respir Dis"},{"issue":"2","key":"10.1016\/j.arbres.2025.10.021_bib0610","first-page":"355","volume":"134","year":"1986","journal-title":"Am Rev Respir Dis"},{"issue":"5","key":"10.1016\/j.arbres.2025.10.021_bib0615","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1164\/ajrccm.149.5.8173779","article-title":"Treatment of tuberculosis and tuberculosis infection in adults and children American Thoracic Society and The Centers for Disease Control and Prevention","volume":"149","author":"Bass","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.arbres.2025.10.021_bib0620","first-page":"1193","article-title":"Joint tuberculosis committee of the British Thoracic Society","volume":"49","year":"1994","journal-title":"Thorax"},{"issue":"4 Pt 2","key":"10.1016\/j.arbres.2025.10.021_bib0625","first-page":"S221","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.arbres.2025.10.021_bib0630","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1183\/13993003.00432-2015","article-title":"Classification of antituberculosis drugs: a new proposal based on the most recent evidence","volume":"2015","author":"Caminero","year":"2015","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.arbres.2025.10.021_bib0635","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.arbr.2020.03.014","article-title":"Update of SEPAR guideline \u201cDiagnosis and Treatment of Drug-Resistant Tuberculosis\u201d","volume":"56","author":"Caminero","year":"2020","journal-title":"Arch Bronconeumol (Engl Ed)"},{"key":"10.1016\/j.arbres.2025.10.021_bib0640","series-title":"The challenge of tuberculosis in the 21st century (ERS Monograph)","first-page":"104","article-title":"The basis of tuberculosis treatment: fundamental concepts before treating a patient","author":"Caminero","year":"2023"},{"issue":"11","key":"10.1016\/j.arbres.2025.10.021_bib0645","first-page":"401","article-title":"Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis","volume":"111","author":"Mart\u00ednez Alfaro","year":"1998","journal-title":"Med Clin (Barc)"},{"issue":"5","key":"10.1016\/j.arbres.2025.10.021_bib0650","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0025-7753(00)71496-5","article-title":"Evaluation of 2 tuberculosis chemoprophylaxis regimens in patients infected with human immunodeficiency virus. The GECMEI Group","volume":"115","author":"Mart\u00ednez Alfaro","year":"2000","journal-title":"Med Clin (Barc)"},{"issue":"6","key":"10.1016\/j.arbres.2025.10.021_bib0655","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0213-005X(03)72942-5","article-title":"Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy","volume":"21","author":"Rivero","year":"2003","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"6","key":"10.1016\/j.arbres.2025.10.021_bib0660","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1086\/520983","article-title":"The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study","volume":"45","author":"Spyridis","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.arbres.2025.10.021_bib0665","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/thx.2009.125054","article-title":"Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB","volume":"65","author":"Aspler","year":"2010","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.arbres.2025.10.021_bib0670","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.arbres.2025.10.021_bib0675","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.arbres.2025.10.021_bib0680","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","article-title":"Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons","volume":"30","author":"Sterling","year":"2016","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.arbres.2025.10.021_bib0685","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid","volume":"169","author":"Villarino","year":"2015","journal-title":"JAMA Pediatr"},{"issue":"2","key":"10.1016\/j.arbres.2025.10.021_bib0690","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.amepre.2018.04.030","article-title":"Isoniazid-rifapentine for latent tuberculosis infection: a systematic review and meta-analysis","volume":"55","author":"Njie","year":"2018","journal-title":"Am J Prev Med"},{"issue":"11","key":"10.1016\/j.arbres.2025.10.021_bib0695","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.arbres.2025.10.021_bib0700","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.cmi.2024.06.024","article-title":"One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial","volume":"30","author":"Huang","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.arbres.2025.10.021_bib0705","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/jac\/dkaf029","article-title":"Pharmacokinetics and safety of rifapentine in children: dosing for latent tuberculosis infection","volume":"80","author":"Liu","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.arbres.2025.10.021_bib0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.eimc.2025.06.002","article-title":"Rifapentine-based treatment of tuberculosis infection in Spanish adolescents","author":"Noguera-Juli\u00e1n","year":"2025","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"5","key":"10.1016\/j.arbres.2025.10.021_bib0715","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1513\/AnnalsATS.201704-326OC","article-title":"Exposure to latent tuberculosis treatment during pregnancy. The PREVENT TB and the iAdhere trials","volume":"15","author":"Moro","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"10 Suppl. 2","key":"10.1016\/j.arbres.2025.10.021_bib0720","first-page":"S61","article-title":"OA07-638-19. Safety of short-course weekly rifapentine and isoniazid (3HP) for TB preventive treatment during pregnancy","volume":"25","author":"Chihota","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"10.1016\/j.arbres.2025.10.021_bib0725","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.arbres.2021.09.016","article-title":"Tuberculosis contacts tracing in Spain: cost analysis","volume":"58","author":"Gull\u00f3n-Blanco","year":"2022","journal-title":"Arch Bronconeumol"},{"issue":"24","key":"10.1016\/j.arbres.2025.10.021_bib0730","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa2314325","article-title":"Levofloxacin for the prevention of multidrug-resistant tuberculosis in Vietnam","volume":"391","author":"Fox","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.arbres.2025.10.021_bib0735","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa2314318","article-title":"Levofloxacin preventive treatment in children exposed to MDR tuberculosis","volume":"391","author":"Hesseling","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.arbres.2025.10.021_bib0740","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400190","article-title":"A meta-analysis of levofloxacin for contacts of multidrug-resistant tuberculosis","volume":"4","author":"Duong","year":"2025","journal-title":"NEJM Evid"},{"key":"10.1016\/j.arbres.2025.10.021_bib0745","series-title":"Tuberculosis among populations at high risk and people in vulnerable situations: policy brief","year":"2025"},{"issue":"6","key":"10.1016\/j.arbres.2025.10.021_bib0750","first-page":"701","article-title":"Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain","volume":"14","author":"Anibarro","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"10.1016\/j.arbres.2025.10.021_bib0755","doi-asserted-by":"crossref","first-page":"315","DOI":"10.5588\/ijtld.22.0611","article-title":"Identifying gaps in the cascade of care for latent TB infection in a low-incidence setting","volume":"27","author":"Grijota-Camino","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.arbres.2025.10.021_bib0760","article-title":"Latent tuberculosis infection treatment completion in Biscay: differences between regimens and monitoring approaches","volume":"10","author":"Ortiz Laza","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"10.1016\/j.arbres.2025.10.021_bib0765","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.5588\/ijtld.14.0271","article-title":"Screening for active tuberculosis in high-risk groups","volume":"18","author":"Jim\u00e9nez-Fuentes","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"10.1016\/j.arbres.2025.10.021_bib0770","doi-asserted-by":"crossref","first-page":"419","DOI":"10.7326\/M14-1019","article-title":"Treatment of latent tuberculosis infection: a network meta-analysis","volume":"161","author":"Stagg","year":"2014","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.arbres.2025.10.021_bib0775","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/pds.4423","article-title":"A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection","volume":"27","author":"Pease","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.arbres.2025.10.021_bib0780","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3904\/kjim.2023.557","article-title":"Adverse drug reactions following treatment of latent tuberculosis infection: a linked national tuberculosis surveillance with claims database","volume":"39","author":"Jung","year":"2024","journal-title":"Korean J Intern Med"},{"issue":"7","key":"10.1016\/j.arbres.2025.10.021_bib0785","article-title":"Adherence and toxicity during the treatment of latent tuberculous infection in a referral center in Spain","volume":"8","author":"Puyana Ortiz","year":"2023","journal-title":"Trop Med Infect Dis"},{"issue":"3","key":"10.1016\/j.arbres.2025.10.021_bib0790","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s10067-021-05969-0","article-title":"Safety of latent tuberculosis infection treatment in older patients with immune-mediated inflammatory diseases","volume":"41","author":"Chung","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.arbres.2025.10.021_bib0795","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(19)30575-4","article-title":"Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials","volume":"20","author":"Campbell","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.arbres.2025.10.021_bib0800","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1097\/QAD.0000000000003613","article-title":"Safety and tolerability of isoniazid preventive therapy for tuberculosis for persons with HIV with and without alcohol use","volume":"37","author":"Hahn","year":"2023","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.arbres.2025.10.021_bib0805","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/cid\/ciad246","article-title":"A systematic review and meta-analysis of tuberculous preventative therapy adverse events","volume":"77","author":"Melnychuk","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.arbres.2025.10.021_bib0810","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02048-2019","article-title":"Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs","volume":"55","author":"Ronald","year":"2020","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.arbres.2025.10.021_bib0815","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.5588\/ijtld.14.0829","article-title":"Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI","volume":"19","author":"Bliven-Sizemore","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"10.1016\/j.arbres.2025.10.021_bib0820","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.cmi.2024.08.009","article-title":"\u2018One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial\u2019 \u2013 author's response","volume":"30","author":"Huang","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"10.1016\/j.arbres.2025.10.021_bib0825","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae667","article-title":"Adverse events reported during weekly isoniazid-rifapentine (3HP) tuberculosis preventive treatment among people with human immunodeficiency virus in Uganda","volume":"11","author":"Kadota","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.arbres.2025.10.021_bib0830","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0000000000004767","article-title":"Completion safety and tolerability of once-weekly isoniazid and rifapentine for tuberculosis infection by children and adolescents","author":"Cruz","year":"2025","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"10.1016\/j.arbres.2025.10.021_bib0835","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.arbres.2025.10.021_bib0840","doi-asserted-by":"crossref","first-page":"506","DOI":"10.5588\/ijtld.23.0078","article-title":"Clinical standards for the management of adverse effects during treatment for TB","volume":"27","author":"Singh","year":"2023","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289625004089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289625004089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:00:36Z","timestamp":1781010036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289625004089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":168,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0300289625004089"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2025.10.021","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations on the Diagnosis and Treatment of Tuberculosis Infection: SEPAR\/SEIMC\/Spanish Ministry of Health Consensus Statement","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2025.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica (SEPAR) and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. Published by Elsevier Espa\u00f1a S.L.U. on behalf of Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica (SEPAR) and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}